Pfm Health Sciences, LP Seagen Inc. Transaction History

Pfm Health Sciences, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $4.85 Million - $5.47 Million	25,318 Added 9.88%	281,617 $59.7 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $6.65 Million - $7.3 Million	35,416 Added 16.03%	256,299 $49.3 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $3.64 Million - $5.79 Million	28,499 Added 14.81%	220,883 $44.7 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $20.3 Million - $24.1 Million	-172,831 Reduced 47.32%	192,384 $24.7 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $11.2 Million - $14.9 Million	82,820 Added 29.33%	365,215 $50 Million

Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $30.7 Million - $50.6 Million	282,395 New	282,395 $50 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $32.1 Million - $42.4 Million	-268,527 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $13.7 Million - $18.3 Million	-96,103 Reduced 26.36%	268,527 $41.5 Million
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $16.9 Million - $20.1 Million	-118,355 Reduced 24.5%	364,630 $61.9 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $65.2 Million - $77.8 Million	482,985 New	482,985 $76.3 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.